Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
- Resource Type
- Article
- Source
- The Lancet; June 2022, Vol. 399 Issue: 10342 p2200-2211, 12p
- Subject
- Language
- ISSN
- 01406736; 1474547X